JAMA Study Bolsters Case for High-Sensitivity Troponin Diagnostics
March 25, 2011
JAMA Study Bolsters Case for High-Sensitivity Troponin Diagnostics
The results could have implications for the future adoption by cardiologists of high-sensitivity troponin assays currently being developed by biotech firms like Singulex and Nanosphere.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Singulex Receives US Patent for Cardiovascular Biomarker Assay, Begins Planning FDA Submission
December 17, 2010 / ProteoMonitor - Abbott Labs Publishes Massive Protein Kinase Dataset, New Statistical Method to Analyze Kinome
March 11, 2011 / ProteoMonitor - MIT, Harvard Team Builds Nanosensor for Monitoring Cumulative Biomarker Exposure
February 18, 2011 / ProteoMonitor - Intrinsic Bioprobes Receives US Patent for Protein Biomarkers for Myocardial Infarction
October 29, 2010 / ProteoMonitor - NCI Kicks Off Second Stage of Clinical Proteomic Technologies for Cancer Initiative
August 26, 2011 / ProteoMonitor